Grail (GRAL) said Wednesday it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study compared with the previous Pathfinder study.
The Pathfinder 2 study was launched in 2021 to assess the safety and performance of the Galleri cancer detection test when added to standard of care in 35,878 adults with more than 50 years of age and with no clinical suspicion of cancer, Grail said.
In Pathfinder 2, adding Galleri to standard of care tests showed "substantially greater additional cancer detection" than in the prior study, the company said.
The results from the latest study also indicated a "substantially higher" positive predictive value than that seen in the previous study, Grail said.
The company also said "no serious safety concerns" were seen in the Pathfinder 2 study.
Grail shares were up more than 4% in recent early trading.
Price: 43.97, Change: +1.92, Percent Change: +4.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。